EDIT Editas Medicine Inc.

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2020.



Conference Call & Webcast Details
Date:Thursday, February 25, 2021 
Time:8:00 am Eastern Time
Toll Free:(844) 348-3801
International:(213) 358-0955
Conference ID:7172199
Webcast:

A live webcast of the conference call can be accessed in the Investors section of Editas Medicine website at .



About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit



Contacts:

Media

Cristi Barnett

(617) 401-0113

Investors

Editas Medicine Investor Relations

(617) 401-9052



EN
18/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Editas Medicine Inc.

 PRESS RELEASE

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results an...

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates by year-end 2024 Initiated enrollment in the adolescent cohort in the RUBY trial Entered into a license agreement providing Vertex Pharmaceuticals a non-exclusive license for Cas9 Strong financial position with operational runway expected into 2026 CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- E...

 PRESS RELEASE

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Co...

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update. To access the conference call: U.S. callers should dial and international callers should dial approximately five minutes before the call...

 PRESS RELEASE

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel: Guggenheim 6th Annual Biotechnology ConferenceFormat: Fireside ChatDate: Wednesday, February 7Time: 9:30 a.m. ETLocation: New York, NY Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFormat: Fireside ChatDate: Tuesday, Feb...

 PRESS RELEASE

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic P...

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP Strong financial position with operational runway into 2026 Company to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. PST CAMBRIDGE, Mass., Jan. 08, 2...

 PRESS RELEASE

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare C...

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA. A of the presentation will be available on the “Investors” section of the Editas Medicine website at . An archived replay will be available on the websi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch